Purple Biotech
PPBT1.3615.49% ( -0.079 )
Purple Biotech (PPBT)
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the U...
- Open
- 1.400
- High
- 1.396
- Low
- 1.361
- Prev. Close
- 1.440
- Volume
- 2.90K
- Turnover
- 3.99K
- Avg Price
- 1.374
- Bid/Ask Ratio
- --
- Amplitude
- 2.43%
- 52wk High
- 24.000
- Volume Ratio
- 0.23
- Turnover Ratio
- 0.03%
Purple Biotech Analyst Rating
View MoreForecast & Rating
May 18, 2026Price forecast
$30.002105.88%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jun 23 at 09:49 AM
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
- Price Alert · Jun 12 at 02:46 AM
U.S. stock night market fluctuations: Aplite rose 3.10% with net inflow from main funds, and biotech stocks slightly increased
- benzinga_article · Jun 11 at 12:05 PM
12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga_article · Jun 11 at 07:05 AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga_article · Jun 11 at 06:17 AM
Purple Biotech shares are trading higher after the company announced the presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at EACR 2026 Annual Congress.
- Tip Ranks · May 15 at 06:28 AM
Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum
